Table 1.

Some important COVID-19 vaccine candidates (www.clinicaltrials.gov) (Accessed November 1, 2021).

Candidate	Type	Clinical trial identifier number	Developer	Delivery system and No. of doses	Clinical trial status	Actual enrolment	Estimated study completion date
BNT162b2	mRNA	NCT04368728	Pfizer-BioNtech	Lipid NPs	Phase III	43998 (estimated)	May 2, 2023
		NCT04760132		Two (separated by 3 weeks)	Phase IV	10000 (estimated)	December 31, 2024
mRNA-1273	mRNA	NCT04470427	Moderna	Lipid NPs	Phase III	30420	October 27, 2022
		NCT04760132		Two (separated by 4 weeks)	Phase IV	10000 (estimated)	December 31, 2024
ChAdOx1 nCoV-19	Non- replicating viral vector	NCT04400838	AstraZeneca/Oxford university	Two (separated by 12 weeks)	Phase II/III	12390 (estimated)	December 31, 2021
Ad26.COV2.S	Non- replicating viral vector	NCT04505722	Janssen Vaccines & Prevention B.V.	One	Phase III	44325	January 2, 2023
Ad5-nCoV	Non- replicating viral vector	NCT04526990	CanSino Biologicals Inc.	One	Phase III	40000 (estimated)	January 30, 2022
Gam-COVID-Vac	Non- replicating viral vector	NCT04530396	Gamaleya Research Institute of Epidemiology and Microbiology	Two (separated by 3 weeks)	Phase III	33758	May 1, 2021
Adsorbed COVID-19 (inactivated) vaccine	Inactivated	NCT04456595	Sinovac Life Sciences Co., Ltd.	Two (separated by 2 weeks)	Phase III	12688	February 2022
		NCT04747821			Phase IV	27711	February 2022
Inactivated SARS-CoV-2 vaccine (Vero cell)	Inactivated	NCT04560881	Sinopharm	Two (separated by 3 weeks)	Phase III	3000	December 1, 2021
BBV152	Inactivated	NCT04641481	Bharat Biotech International Limited	Two (separated by 4 weeks)	Phase III	25800	December 2022
SARS-CoV-2rS/Matrix-M-1 Adjuvant	Protein subunit	NCT04611802	Novavax	Two (separated by 3 weeks)	Phase III	33000 (estimated)	June 30, 2023